After achieving primary endpoint by demonstrating non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec helped patients achieve significantly more time in target blood glucose range (Time in Range) vs. once-daily basal insulin glargine U100 in ONWARDS…